Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 6:2022:5000948.
doi: 10.1155/2022/5000948. eCollection 2022.

Meta-Analysis of Naoxintong Capsule for Patients with Vascular Dementia

Li Li  1   2 , Yawei Zheng  2   3 , Jinjing Bao  1   2 , Yandong Zhao  1   2 , Qiuchi Zhang  1   2 , Wenlei Li  1   2 , Minghua Wu  1   2
Affiliations
Review

Meta-Analysis of Naoxintong Capsule for Patients with Vascular Dementia

Li Li et al. Evid Based Complement Alternat Med. .

Abstract

Background: Vascular dementia (VaD) is the second most common form of dementia among the elderly. There is currently no unequivocal recommendation of an effective treatment option for VaD.

Objective: The purpose of this study was to evaluate the efficacy and safety of Naoxintong capsule (NXT) in the treatment of VaD patients.

Methods: We searched for randomized controlled trials (RCTs) published before September 2021 in PubMed, Embase, Web of Science, Cochrane Library, CNKI, VIP, and Wanfang databases. The trials assessed the efficacy and/or safety of NXT in treating patients with VaD. A meta-analysis was then performed using Stata 14.0 software.

Results: A total of 33 studies comprising 2,947 patients with VaD were included in this study. The meta-analysis revealed that NXT improved cognitive function in VaD patients, increased the mini-mental state examination (MMSE) score by 3.33 points (WMD = 3.33, 95% CI (2.72, 3.94)), the Montreal Cognitive Assessment (MoCA) score by 4.31 points (WMD = 4.31, 95% CI (2.72, 5.90)), and the Hasegawa dementia scale (HDS) by 2.71 points (WMD = 2.71, 95% CI (1.26, 4.17)). Furthermore, NXT significantly improved the daily lives of VaD patients, lowering the activities of daily living (ADL) score by 5.85 points (WMD = -5.85, 95% CI (-7.03, -4.66)). NXT improved the total effective rate (TER) (OR = 2.62, 95% CI (2.09, 3.29)) of the patients without increasing the occurrence of adverse events (AEs; OR = 0.72, 95% CI (0.43, 1.22)). Subgroup analysis revealed that whether NXT was used alone or in combination with western medicine, it could enhance the overall curative effect.

Conclusions: NXT may be an effective and safe treatment option for VaD. However, because of the limited number and quality of articles included, this study's findings need to be validated by additional high-quality, large-sample, and multicenter RCTs (Systematic Review Registration Number: PROSPERO; https://clinicaltrials.gov/ct2/show/CRD42021233199).

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Figures

Figure 1
Figure 1
Flow chart for literature screening.
Figure 2
Figure 2
Risk of bias summary.
Figure 3
Figure 3
Risk of bias.
Figure 4
Figure 4
Forest plot for MMSE of NXT in vascular dementia.
Figure 5
Figure 5
Funnel plot for MMSE of NXT in vascular dementia.
Figure 6
Figure 6
Forest plot for MoCA of NXT in vascular dementia.
Figure 7
Figure 7
Forest plot for HDS of NXT in vascular dementia.
Figure 8
Figure 8
Forest plot for ADL of NXT in vascular dementia.
Figure 9
Figure 9
Funnel plot for ADL of NXT in vascular dementia.
Figure 10
Figure 10
Forest plot for TER of NXT in vascular dementia.
Figure 11
Figure 11
Funnel plot for TER of NXT in vascular dementia.
Figure 12
Figure 12
Forest plot for AEs of NXT in vascular dementia.
Figure 13
Figure 13
Sensitivity analysis: (a) MMSE, (b) MoCA, (c) HDS, (d) ADL, (e) TER, and (f) AEs.
See this image and copyright information in PMC

References

    1. Smith E. E. Clinical presentations and epidemiology of vascular dementia. Clinical Science . 2017;131(11):1059–1068. doi: 10.1042/CS20160607. - DOI - PubMed
    1. Hugo J., Ganguli M. Dementia and cognitive impairment. Clinics in Geriatric Medicine . 2014;30(3):421–442. doi: 10.1016/j.cger.2014.04.001. - DOI - PMC - PubMed
    1. van der Flier W. M., Scheltens P. Epidemiology and risk factors of dementia. Journal of Neurology, Neurosurgery & Psychiatry . 2005;76(suppl_5):v2–v7. doi: 10.1136/jnnp.2005.082867. - DOI - PMC - PubMed
    1. McVeigh C., Passmore P. Vascular dementia: prevention and treatment. Clinical Interventions in Aging . 2006;1(3):229–235. doi: 10.2147/ciia.2006.1.3.229. - DOI - PMC - PubMed
    1. Raz L., Knoefel J., Bhaskar K. The neuropathology and cerebrovascular mechanisms of dementia. Journal of Cerebral Blood Flow & Metabolism . 2016;36(1):172–186. doi: 10.1038/jcbfm.2015.164. - DOI - PMC - PubMed

LinkOut - more resources